Bath University spin-out Glythera to collaborate with FDA

Collaboration

Glythera Ltd is to collaborate with the US Food and Drug Administration (FDA) to assess the feasibility of applying Glythera’s PermaLink technology to generate synthetic carbohydrate-based conjugate vaccines.

The Bath University spin-out will work with the Centre for Biologics Evaluation and Research at the FDA to adapt its PermaLink technology to develop carbohydrate-based vaccines.

“We are delighted to enter into this direct collaboration with the FDA” says Anthony Baxter, Chairman of Glythera. “This programme will allow us to demonstrate the versatility of our PermaLink technology for application in this important field of vaccine development.”